Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

You are trying to reach document intended for healthcare professionals only

Letters to HCPs

{pdf_link}

Edarbi

{healthcare_pro_orange} For Healthcare Professionals

Takeda would like to inform you that Edarbi® (azilsartan medoxomil), an Angiotensin II receptor blocker (ARB) for the treatment of essential hypertension in adults, is being withdrawn from the UK market. Edarbi will continue to be available in the UK until the end of 2026. The established therapeutic efficacy and safety of Edarbi remains unchanged.

Are you a healthcare professional?